Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-2.77 · Revenue $42.79M · 4 analysts
Est. EPS $-0.20 · Revenue $56.91M · 1 analysts
Est. EPS $-0.14 · Revenue $64.22M · 2 analysts
Est. EPS $-2.06 · Revenue $175.43M · 3 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-313.9M | -26.9% | +4.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-284.6M | -43.0% | -34.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 67.2% | +266.7% | +57.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.79x | -39.7% | +9.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $332.4M | -39.7% | -24.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.38 vs -3.25 | -3.9% | -0.72 vs -0.20 | -260.0% |
| Revenue Surprise | $0 vs $4.4M | -100.0% | $0 vs $56.9M | -100.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Astley-Sparke Philip | director | Common Stock | D | 50,000 | — |
| Aug 17, 2026 | Hill Emily Luisa | officer: Chief Financial Officer | Common Stock | D | 9,256 | $14.28 |
| Aug 11, 2026 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 2026 $0.0001 Prefunded Warrants | A | 2,609,946 | $0.00 |
| Aug 11, 2026 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 2026 $0.0001 Prefunded Warrants | A | 126,394 | $0.00 |
| Aug 10, 2026 | Patel Sushil | director, officer: Chief Executive Officer | Common Stock | D | 39,341 | $12.97 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Sushil Patel | Chief Executive Officer & Director | USD 1,021,654 | Male | 1971 | Active |
Philip Astley-Sparke | Executive Chairman | USD 960,520 | Male | 1971 | Active |
Konstantinos Xynos | Chief Medical Officer | USD 748,530 | — | 1966 | Active |
Emily Luisa Hill | Chief Financial Officer | USD 728,320 | Female | 1980 | Active |
Carolyn Trott | Senior Vice President of Quality Assurance | — | Female | — | Active |
Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management | — | Female | — | Active |
Camilo Garcia | Chief Human Resource Officer | — | Male | — | Active |
Andrew Schwendenman | Chief Accounting Officer & Treasurer | — | Male | 1976 | Active |
Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | — | Male | — | Active |
Shawn Glidden | Senior Vice President & General Counsel | — | Male | — | Active |
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL P
LOS ANGELES, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
NEW YORK, Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Replimune shareholders who bought REPL stock between October 20, 2025 and April 10, 2026 retain specific rights under the federal securities laws after the FDA's rejection of the RP1 biologics license application allegedly erased more than 80% of the stock's Class Period value Replimune shareholders who bought REPL stock between October 20, 2025 and April 10, 2026 retain specific rights under the federal securities laws after the FDA's rejection of the RP1 biologics license application allegedly erased more than 80% of the stock's Class Period value
San Diego, California--(Newsfile Corp. - August 17, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies.
